UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 22, 2015
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
Nevada | 001-35756 | 74-2897368 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida |
33913 | |
(Address of principal executive offices) | (Zip Code) |
(239) 768-0600
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. | Results of Operations and Financial Condition. |
On January 22, 2015, NeoGenomics, Inc. (the Company) issued a press release regarding its raising of its revenue and earnings-per-share guidance for the fourth quarter of 2014 (the Press Release). A complete copy of the Press Release is attached hereto as Exhibit 99.1.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 furnished pursuant to Item 9.01, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 of this Current Report on Form 8-K, , including Exhibit 99.1 furnished pursuant to Item 9.01, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act of 1934.
Item 9.01. | Financial Statements and Exhibits. |
(a) | Not applicable |
(b) | Not applicable |
(c) | Not applicable |
(d) | Exhibits. |
99.1 | Press Release of NeoGenomics, Inc. dated January 22, 2015. |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOGENOMICS, INC. | ||
By: | /s/ Douglas VanOort | |
Douglas VanOort | ||
Chief Executive Officer |
Date: January 23, 2015
- 3 -
Exhibit Index
Exhibit |
Description | |
99.1 | Press Release of NeoGenomics, Inc. dated January 22, 2015 |
- 4 -
Exhibit 99.1
NEOGENOMICS, INC.
PRESS RELEASE
FOR IMMEDIATE RELEASE
NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014
Company Now Projecting 36% Year-Over-Year Revenue Growth in Quarter 4
Ft. Myers, Florida January 22, 2015 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue and earnings-per-share guidance for the fourth quarter of 2014. The Company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter. Previously, the Company had issued revenue guidance of $23.0 - $24.5 million and earnings-per-share guidance of $0.00 - $0.01 per share.
Douglas VanOort, the Companys Chairman and CEO, commented, On a consolidated basis, including the results of our newly acquired PathLogic business, we are expecting approximately 36% year-over-year revenue growth in the fourth quarter. Approximately 23% of this growth is coming from our core NeoGenomics business and the remainder from PathLogic. The improvement in earnings guidance reflects continued strength in our underlying business. We look forward to sharing our final audited fourth quarter financial results and to reviewing key growth initiatives as part of our Quarter 4 Earnings Release and Conference Call, both of which are scheduled for February 24, 2015.
The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Companys securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIAcertified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The companys testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
1
Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from Zacks Investment Research at http://www.zacks.com or scr@zacks.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the companys ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the companys periodic filings with the SEC.
For further information, please contact:
NeoGenomics, Inc. | Hawk Associates, Inc. | |
Steven C. Jones | Ms. Julie Marshall | |
Director of Investor Relations | (305)-451-1888 | |
(239) 325-2001 | (212) 825-3210 | |
sjones@neogenomics.com | neogenomics@hawkassociates.com |
2
DX^]#,EY!8[0'JA!,_%.+/*X-\A8M#W&@+\`_AVA
ME1#?\0Z]H?7H^L1Z0@J?4K^@KT3&.^EX0O[D^(1[=Q!2Z;;;[@`W.;`0#;J&
MFKO,$]Z5F&/ZO]VC_;$3M@G[&;\*_2(_(!"K_6)H&4.->?<>^HQB:+0G*:ZK
M,7A/DG'*4ZEW9S%UI&;3=5RTH1=Z@;)76:KMNJ+%%^NU,1F\0;%./C<&U9O=
M!7VO<5DJ>[F[N%NM4X:BB4EUQH%S3I6A2FU)41D=(.()EB(J_O,H*^SW1G>E
MN1J9T!JH!;0Y),Q)82L%(F)C409$##&-%X`K=NYL$5Y%(UW)5PQE`.W$;6@H
M^,>`$46)6B'@O'+.]U^=FZPUC#HH=JC@KAD3YH=C;@B!=Y[ G/E?)^.YYI9J3>L5P5FK4XR$?!(14E,P:J*O8/QMW"1NY-9$^RB"Q#)G`#%
M$-?-NS+?5VGO%I;7<$%JN8JE(6@\%!*ICI'$'(C$1]!7"NI;EMI5PHE!=(\R
M%)/,$B6'`\PIUL7B*;EH\:N4CHN
M&KINL4Z+ANND<2'(69&1A,NY"OURSL9.,M=?2W$_P!EKI'>-C``M3'``(21HZ]]
M@H2A;C>DSFA:D'I'5(Q//A'%54--4I(=:;J'*E(P#=4Q5)$L<6W@EXSZ?!&%H-,-\@L63==SA`<9(*Q
M"=Y`6T^6N$>1,"6:NRRQET65@C,\X95<4Z`F#'*90BZS/8JZ9R"D9/L#M?\`9^D.(+5>W4(<1AU#3/Z"I///AC..-35MO%"MNYMT27YE)+M&
MMA:?GI>9"D@\03+IB[PU